Everolimus-based immunosuppression induces alloreactive regulatory T cell expansion combined with loss of alloreactive effector T cells.

Litjens NHR, Jonker J, Klepper M, Prevoo F, Hesselink DA

RANDOMISERAD CONTROLLED TRIAL Nivå 2 2026

StudiedesignRANDOMISERAD CONTROLLED TRIAL

TierNivå 2, Strong humana bevis, hard endpoints or biomarkörer

År2026

TidskriftFrontiers i immunology

Publicerad2026

Tillagd i NO1GEVITYaug 20, 2026

Citerad av

1 encyklopediartiklar refererar till denna studie.